Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Objective: Recent randomized and controlled trials of drugs derived from the gut hormone glucagon-like peptide-1 (GLP-1) show that the most frequent adverse symptoms are gastrointestinal, including gallbladder-related side effects such as cholithiasis and cholecystitis. Since the gut hormone cholecystokinin (CCK) stimulates bile secretion and regulates gallbladder motility and emptying, we examined the effect of GLP-1 on the secretion of CCK in normal subjects and patients with type 1 diabetes mellitus. Materials and methods: Plasma was sampled from 10 healthy subjects and 10 patients with diabetes. With plasma glucose concentrations clamped between 6 and 9 nmol/l, GLP-1 or saline was infused for 240 min during and after a meal. The plasma concentrations of CCK were measured with a highly specific radioimmunoassay. Results: Basal plasma concentrations of CCK were similar in the normal subjects and in the diabetes patients. During the meal, the CCK concentrations rose significantly during saline infusion, whereas the GLP-1 infusion suppressed the secretion of CCK significantly in both normal subjects and in the diabetes patients. Conclusions: The results show that GLP-1 suppresses the secretion of CCK after a meal in normal and diabetic subjects. The suppression attenuates the gallbladder contractility. Our data, therefore, offer an explanation for the increased risk of adverse gallbladder events during treatment with GLP-1-derived drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 hinders gallbladder motility and postpones gallbladder evacuation by inhibiting cholecystokinin secretion [40-44].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [43]
In the citing paper
“GLP-1 has been shown to impair gallbladder motility and contractility by inhibiting the secretion of cholecystokinin, a hormone involved in the digestion and absorption of fat, which may contribute to the development of gallbladder or biliary disease (40).”
From Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis (2023) · cites this paper as [40]
In the citing paper
“In fact, GLP-1RA hinder gallbladder motility and emptying by reducing cholecystokinin secretion [23].”
From The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2024) · cites this paper as [23]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“Due to stimulation of insulin and inhibition of glucagon secretion, the gut hormone GLP-1 has been a target for development of new diabetes drugs [7,8].”
BackgroundSelf-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Due to stimulation of insulin and inhibition of glucagon secretion, the gut hormone GLP-1 has been a target for development of new diabetes drugs [7,8].”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Somatostatin Cell Processes as Pathways for Paracrine Secretion
Larsson, L.-I., Goltermann, N., de Magistris, L., Rehfeld, J. F., & Schwartz, T. W. (1979) · Science · doi:10.1126/science.382360 · Cited by 511 · cited 1×
“Examples include the paracrine and endocrine inhibitory effects of somatostatin on the secretion of most hormones in the gut and the pancreas [3,4]; the stimulatory effect of cholecystokinin (CCK) on somatostatin secretion in the gastric fundus [5]; and the stimulatory effects of gastrin and CCK peptides on glucagon-l…”
BackgroundSelf-citationExpression cloning and characterization of the canine parietal cell gastrin receptor.
Kopin, A. S., Lee, Y. M., McBride, E. W., Miller, L. J., Lu, M., Lin, H. Y., Kolakowski, L. F., & Beinborn, M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3605 · Cited by 508
Cholecystokinin and Gastrin Receptors
Dufresne, M., Seva, C., & Fourmy, D. (2006) · Physiological Reviews · doi:10.1152/physrev.00014.2005 · Cited by 476 · cited 3×
“Of interest in a GLP-1 and diabetes context is the fact that pancreatic islet cells in man, pig, and mouse express also the CCK2-receptor [27,29,30].”
BackgroundAccurate measurement of cholecystokinin in plasma
Rehfeld, J. F. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.5.991 · Cited by 320 · cited 1×
“92128, which has a unique specificity for the a-amidated and O-sulfated C-terminus and measures all bioactive forms of CCK in circulation without cross-reactivity with any gastrin peptide [20].”
BackgroundSelf-citationCholecystokinin—From Local Gut Hormone to Ubiquitous Messenger
Rehfeld, J. F. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00047 · Cited by 265 · cited 3×
“, physiological) affinity, and the gallbladder myocytes express only the CCK1-receptor [17,18,25].”
BackgroundSelf-citation
Research works printed but not linked: 3
- Kumar U, 2010, Results Probl Cell Differ, 50, 137
- Wank SA, 1995, Am J Physiol, 269, G628
- Rehfeld JF, 2001, J Clin Endocrinol Metab, 86, 251
Cited by
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“Moreover, both GLP-1 (70) and GLP-1RAs [eg, exenatide (71), albiglutide (72), and liraglutide (73)] have been shown to inhibit gallbladder emptying and refilling and to potentially reduce the discharge of bile into the small intestine, in-terrupting the subsequent emulsification and digestion of…”
Nauck, M. A., Muus Ghorbani, M. L., Kreiner, E., Saevereid, H. A., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2019) · Diabetes Care · doi:10.2337/dc19-0415 · Cited by 69
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
“GLP-1 has been shown to impair gallbladder motility and contractility by inhibiting the secretion of cholecystokinin, a hormone involved in the digestion and absorption of fat, which may contribute to the development of gallbladder or biliary disease (40).”
BackgroundJalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Metadata
- Authors
- Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Rehfeld, Jens F.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2018-11-19
- Volume
- 53
- Issue
- 12
- Pages
- 1429-1432
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2901921552
- Cited by
- 62
- References
- 34
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 13 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 3 · 2019: 2
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Scandinavian Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Amgen
- AstraZeneca
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- cholecystokinin, glucagon-like peptide-1, GLP-1 receptor agonists, cholecystitis, gallbladder motility, type 1 diabetes, bile secretion
- MeSH terms
- Adult, Blood Glucose, Cholecystokinin, Diabetes Mellitus, Type 1, Female, Gallbladder, Humans, Male, Case-Control Studies, Gallbladder Emptying, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. https://app.cochat.ai/papers/10.1080/00365521.2018.1530297
- The paper
- Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M. (2018). Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365521.2018.1530297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.